Nasdaq · SEC CIK 0001048477
This is the supported SEC-traceable subset, not total insider ownership or personal wealth. Values reflect the current disclosed positions Grizzly Bulls can resolve and value. Latest source filing: Sep 3, 2026 · values through Sep 25, 2026.
Filter the reporting-owner snapshot by holder, role, or security. Position values are shown only where the current reviewed data supports them.
| Holder | Role | Position | Current value | Latest filing |
|---|---|---|---|---|
| George Eric DavisResearch disclosed relationships | EVP, Chief Legal Officer | 61,003 sharesCommon Stock, par value $0.001 | $3.68M | Sep 3, 2026 |
These relationships are joined only when the same single SEC reporting-owner CIK appears unambiguously across the publication-authorized company ownership universe. Name similarity is never used to create a relationship.
SEC reporting-owner CIK 0001380710 · 1 published company relationship
| Company | SEC relationship | Covered position | Current covered value | Latest filing | Research |
|---|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq · Current company | EVP, Chief Legal Officer | 61,003 sharesCommon Stock, par value $0.001 | $3.68M | Sep 3, 2026 |
This graph is bounded to the company ownership relationships currently published by Grizzly Bulls. It is not a complete employment, board, ownership, portfolio, or wealth history, and a missing relationship does not establish that none exists.
Each row preserves the reviewed SEC transaction evidence, including the effective-date basis, amendment state, reported post-transaction position when present, and a separately published current covered owner/security position when one can be matched uniquely. Reported price is shown when present. The lab does not calculate gross proceeds, reconstruct balances between filings, or treat historical transactions as current wealth.
| Effective date | Holder | Action | Security | Units | Reported price | Reported position after transaction | Current covered position | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026Transaction date | George Eric DavisResearch disclosed relationships | SaleSEC code S | Common Stock, par value $0.001 | 17,557 shares | $66.284 | 61,003 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed Sep 3, 2026 |
| Jun 8, 2015Transaction date | George Eric DavisResearch disclosed relationships | DispositionSEC code G | Common Stock, par value $0.001 | 120 shares | $0 | 67,618 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed Jun 8, 2015 |
| Jun 4, 2015Transaction date | George Eric DavisResearch disclosed relationships | DispositionSEC code F | Common Stock, par value $0.001 | 1,488 shares | $120.46 | 67,738 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed Jun 8, 2015 |
| May 18, 2015Transaction date | George Eric DavisResearch disclosed relationships | SaleSEC code S | Common Stock, par value $0.001 | 2,558 shares | $125.26 | 69,226 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed May 19, 2015 |
| May 15, 2015Transaction date | George Eric DavisResearch disclosed relationships | DispositionSEC code F | Common Stock, par value $0.001 | 1,096 shares | $122.78 | 71,784 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed May 19, 2015 |
| May 8, 2015Transaction date | George Eric DavisResearch disclosed relationships | DispositionSEC code F | Common Stock, par value $0.001 | 1,696 shares | $121.66 | 72,880 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed May 12, 2015 |
| Apr 30, 2015Transaction date | George Eric DavisResearch disclosed relationships | AcquisitionSEC code A | Common Stock, par value $0.001 | 730 shares | $51.2635 | 74,576 shares | 61,003 sharesOwner coverage latest filing Sep 3, 2026 | 4Filed May 12, 2015 |
A reported post-transaction position is the balance stated in that historical transaction filing. A current covered position is a separate latest owner/security observation and may reflect later filings or activity. They are shown side by side as evidence points, not as a reconstructed continuous ledger.
Published 7 of 7 source candidates under the current reviewed security-resolution rules.
| Security | Instrument family | Covered positions | Covered value |
|---|---|---|---|
| Common Stock, par value $0.001 | ordinary-share | 1 | $3.68M |
Current holdings: direct positions that the reviewed ownership data can trace to an exact reporting owner, legal security, and current-basis quantity.
Current value: the existing published company-position valuation. This lab does not recalculate security values or infer missing positions.
Transaction evidence: historical flow observations with filing provenance. Reported post-transaction balances and current covered positions are separate evidence points; the lab does not interpolate ownership between them.
Reporting-owner graph: exact reporting-owner CIK relationships across the published company universe. It does not merge people by name or create a complete personal history.
Not included here: a claim of total insider ownership, total personal wealth, institutional 13F ownership, a transaction-value estimate, an insider sentiment score, or an investment recommendation.
This sequence orders only the ownership evidence already published by Grizzly Bulls for the exact reporting-owner relationships above. Transaction rows are ordered by filing date while preserving the separate economic effective date and its basis. Current covered snapshots remain separate latest observations.
The chronology does not interpolate ownership between entries, infer missing activity, pair an amended filing with an assumed parent, infer amendment supersession, or treat a current covered snapshot as proof of continuous ownership.
| Evidence date | Company | Observation | Security / position | Source |
|---|---|---|---|---|
| Sep 3, 2026Latest represented filing date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | Current covered snapshotEVP, Chief Legal OfficerValuation observation Sep 25, 2026 | Common Stock, par value $0.001: 61,003 sharesCurrent covered company value: $3.68M | Published current ownership snapshotForms represented: 4Owner filingsIssuer filings |
| Sep 3, 2026Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | SaleSEC code SEffective Sep 2, 2026 · transaction dateReported units 17,557 shares · reported price 66.284 | Common Stock, par value $0.001Reported position after transaction: 61,003 shares | 4 filing0001628280-26-060572 |
| Jun 8, 2015Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | DispositionSEC code FEffective Jun 4, 2015 · transaction dateReported units 1,488 shares · reported price 120.46 | Common Stock, par value $0.001Reported position after transaction: 67,738 shares | 4 filing0001140361-15-023529 |
| Jun 8, 2015Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | DispositionSEC code GEffective Jun 8, 2015 · transaction dateReported units 120 shares · reported price 0 | Common Stock, par value $0.001Reported position after transaction: 67,618 shares | 4 filing0001140361-15-023529 |
| May 19, 2015Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | DispositionSEC code FEffective May 15, 2015 · transaction dateReported units 1,096 shares · reported price 122.78 | Common Stock, par value $0.001Reported position after transaction: 71,784 shares | 4 filing0001140361-15-020974 |
| May 19, 2015Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | SaleSEC code SEffective May 18, 2015 · transaction dateReported units 2,558 shares · reported price 125.26 | Common Stock, par value $0.001Reported position after transaction: 69,226 shares | 4 filing0001140361-15-020974 |
| May 12, 2015Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | AcquisitionSEC code AEffective Apr 30, 2015 · transaction dateReported units 730 shares · reported price 51.2635 | Common Stock, par value $0.001Reported position after transaction: 74,576 shares | 4 filing0001140361-15-019205 |
| May 12, 2015Filed date | BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq | DispositionSEC code FEffective May 8, 2015 · transaction dateReported units 1,696 shares · reported price 121.66 | Common Stock, par value $0.001Reported position after transaction: 72,880 shares | 4 filing0001140361-15-019205 |
Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 7 published transaction rows for this exact reporting-owner CIK appear in the chronology.
These handoffs preserve the exact company identities already represented in the reporting-owner graph. My Stocks keeps a listed company in your existing research lists. Research Inbox is a separate company-change update workflow.
Saving a company to My Stocks never enables updates, and opening Research Inbox never subscribes you automatically. Each update remains an explicit company-level opt-in under the existing Research Inbox consent flow.
| Company | Reporting-owner context | Published evidence | Continue research |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN)Nasdaq · Current company | George Eric DavisSEC CIK 00013807108 chronology observations | 8Published chronology observationsLatest represented evidence Sep 3, 2026 |
These are company-level continuation paths, not reporting-owner subscriptions. Saving or watching one company does not automatically save or watch the other companies connected to the same reporting owner, and it does not create an owner-level alert.
